Targeted immunology for prevention and cure of VL

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Ali, Nahid ^a   Nakhasi, Hira L ^b   Valenzuela, Jesus G ^c   Reis, Alexandre Barbosa ^d  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

Immuno modulator; Immunotherapy; Th1 response; Vaccine; Visceral leishmaniasis

Indexed keywords

ANTIBODY; CYTOKINE; DNA VACCINE; EPITOPE; LIVE VACCINE; MILTEFOSINE; SALIVA PROTEIN; STIBOGLUCONATE SODIUM;

ANEMIA; ANTIGEN PRESENTING CELL; ANTIGENICITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; EDITORIAL; FEVER; FLY BITE; HEPATOSPLENOMEGALY; HUMAN; IMMUNITY; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; NONHUMAN; PHAGOCYTE; TH1 CELL; TRANSGENIC ORGANISM; UNSPECIFIED SIDE EFFECT; VISCERAL LEISHMANIASIS; WEIGHT REDUCTION;

EID: 84919472348     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00660     Document Type: Editorial

References (25)

1. Stauch A, Duerr HP, Picado A, Ostyn B, Sundar S, Rijal S, et al. Model-based investigations of different vector-related intervention strategies to eliminate visceral leishmaniasis on the Indian subcontinent. PLoS Negl Trop Dis (2014) 8(4):e2810. doi: 10.1371/journal.pntd.0002810
2. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One (2012) 7(5):e35671. doi:10.1371/journal.pone.0035671
3. Palatnik-de-Sousa CB. Vaccines for canine leishmaniasis. Front Immunol (2012) 3:69. doi:10.3389/fimmu.2012.00069
4. Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol (2011) 9(8):604-15. doi:10.1038/nrmicro2608
5. Cecilio P, Perez-Cabezas B, Santarem N, Maciel J, Rodrigues V, Cordeiro da Silva A. Deception and manipulation: the arms of Leishmania, a successful parasite. Front Immunol (2014) 5:480. doi:10.3389/fimmu.2014.00480
6. Kumar R, Nylen S. Immunobiology of visceral leishmaniasis. Front Immunol (2012) 3:251. doi:10.3389/fimmu.2012.00251
7. Fan K, Borden E, Yi T. Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo. J Interferon Cytokine Res (2009) 29(8):451-60. doi:10.1089/jir.2008.0061
8. Wadhone P, Maiti M, Agarwal R, Kamat V, Martin S, Saha B. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. J Immunol (2009) 182(11):7146-54. doi:10.4049/jimmunol.0803859
9. Singh OP, Sundar S. Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. Front Immunol (2014) 5:296. doi:10.3389/fimmu.2014.00296
10. Nico D, Gomes DC, Palatnik-de-Sousa I, Morrot A, Palatnik M, Palatnik-de-Sousa CB. Leishmania donovani nucleoside hydrolase terminal domains in cross-protective immunotherapy against Leishmania amazonensis murine infection. Front Immunol (2014) 5:273. doi:10.3389/fimmu.2014.00273
11. Roatt BM, Aguiar-Soares RD, Coura-Vital W, Ker HG, Moreira N, Vitoriano-Souza J, et al. Immunotherapy and immunochemotherapy in visceral Leishmaniasis: promising treatments for this neglected disease. Front Immunol (2014) 5:272. doi:10.3389/fimmu.2014.00272
12. Chouhan G, Islamuddin M, Sahal D, Afrin F. Exploring the role of medicinal plant-based immunomodulators for effective therapy of leishmaniasis. Front Immunol (2014) 5:193. doi:10.3389/fimmu.2014.00193
13. Joshi S, Rawat K, Yadav NK, Kumar V, Siddiqi MI, Dube A. Visceral Leishmaniasis: advancements in vaccine development via classical and molecular approaches. Front Immunol (2014) 5:380. doi:10.3389/fimmu.2014.00380
14. Nico D, Gomes DC, Alves-Silva MV, Freitas EO, Morrot A, Bahia D, et al. Cross-protective immunity to Leishmania amazonensis is mediated by CD4+ and CD8+ epitopes of Leishmania donovani nucleoside hydrolase terminal domains. Front Immunol (2014) 5:189. doi:10.3389/fimmu.2014.00189
15. Aebischer T. Leishmania spp. proteome data sets: a comprehensive resource for vaccine development to target visceral leishmaniasis. Front Immunol (2014) 5:260. doi:10.3389/fimmu.2014.00260
16. Das S, Freier A, Boussoffara T, Oswald D, Losch FO, Selka M, et al. Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. Sci Transl Med (2014) 6(234):234ra56. doi:10.1126/scitranslmed.3008222
17. Agallou M, Athanasiou E, Koutsoni O, Dotsika E, Karagouni E. Experimental validation of multi-epitope peptides including promising MHC class I- and II-restricted epitopes of four known Leishmania infantum proteins. Front Immunol (2014) 5:268. doi:10.3389/fimmu.2014.00268
18. Majumder S, Bhattacharjee A, Paul Chowdhury B, Bhattacharyya Majumdar S, Majumdar S. Antigen-pulsed CpG-ODN-activated dendritic cells induce host-protective immune response by regulating the t regulatory cell functioning in Leishmania donovani-infected mice: critical role of CXCL10. Front Immunol (2014) 5:261. doi:10.3389/fimmu.2014.00261
19. Titus RG, Ribeiro JM. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science (1988) 239(4845):1306-8. doi:10.1126/science.3344436
20. Gomes R, Oliveira F, Teixeira C, Meneses C, Gilmore DC, Elnaiem DE, et al. Immunity to sand fly salivary protein LJM11 modulates host response to vector-transmitted Leishmania conferring ulcer-free protection. J Invest Dermatol (2012) 132(12):2735-43. doi:10.1038/jid.2012.205
21. Gomes R, Teixeira C, Teixeira MJ, Oliveira F, Menezes MJ, Silva C, et al. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci U S A (2008) 105(22):7845-50. doi:10.1073/pnas.0712153105
22. Kamhawi S, Aslan H, Valenzuela JG. Vector saliva in vaccines for visceral leishmaniasis: a brief encounter of high consequence? Front Public Health (2014) 2:99. doi:10.3389/fpubh.2014.00099
23. Saljoughian N, Taheri T, Rafati S. Live vaccination tactics: possible approaches for controlling visceral leishmaniasis. Front Immunol (2014) 5:134. doi:10.3389/fimmu.2014.00134
24. Chhajer R, Ali N. Genetically modified organisms and visceral leishmaniasis. Front Immunol (2014) 5:213. doi:10.3389/fimmu.2014.00213
25. Gannavaram S, Dey R, Avishek K, Selvapandiyan A, Salotra P, Nakhasi HL. Biomarkers of safety and immune protection for genetically modified live attenuated Leishmania vaccines against visceral leishmaniasis-discovery and implications. Front Immunol (2014) 5:241. doi:10.3389/fimmu.2014.00241